Cassian Yee, MD
Medical Oncology · Houston, TXNPI 1932301280
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,911 of the $20,703 with a category attached, or 91.3%. 5 manufacturers reported payments, led by Merck at 58.9% of the total. Reporting peaked in 2024 at $12,200 and has fallen 99.8% since, to $22 in 2025.
Across 6 payments — averaging $3450.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$12K
- GSK$5K
- Genentech, Inc.$3K
- Immunocore Limited$38
- Janssen Research & Development, LLC$22
Across 1 payment — averaging $40,625 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$41K
What the payments were for
- Consulting fees$18,91191%
- Travel & lodging$1,7328%
- Food & beverage$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $12,200 |
| GSK | 2 | $5,443 |
| Genentech, Inc. | 1 | $3,000 |
| Immunocore Limited | 1 | $38 |
| Janssen Research & Development, LLC | 1 | $22 |
How this compares
$20,703 in reported general payments places this provider in the 70th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.